MyAverix Finance MyAverix Finance

STU

Celldex Therapeutics Inc (TCE2)

Celldex Therapeutics Inc (TCE2) is listed on STU. As of 2026-03-24, reported P/E ratio is 18.00. Use this page for a quick overview, then open the MyAverix Finance app for income statements, balance sheet, cash flow, and news.

Data as of 2026-03-24

Download on the App Store Get it on Google Play

Download free on iPhone and Android

Key metrics for TCE2

P/E ratio
18.00

Celldex Therapeutics Inc (TCE2) — FAQ

What is TCE2's P/E ratio?

The price-to-earnings (P/E) ratio for Celldex Therapeutics Inc (TCE2) is 18.00 (data as of 2026-03-24).

Does Celldex Therapeutics Inc pay a dividend?

Dividend yield is not available in the current snapshot for Celldex Therapeutics Inc (TCE2). Check the MyAverix Finance app for the latest dividend data.

What exchange is TCE2 listed on?

TCE2 is listed on STU.

Full report in the app

Get the full report in the MyAverix Finance app — income, balance sheet, cash flow, ratios, and multi-year trends in one place.

← All stocks

MyAverix Finance provides company information and financial data for educational and research purposes only. We are not a broker, advisor, or investment service. Data may be delayed or incomplete. Past performance does not guarantee future results. Always do your own research before making financial decisions.

Terms of Use

App Store Google Play